Mr. Speaker, Bloomberg reports that the Gates Foundation and two U.S. companies want to expand U.S. production of monoclonal antibodies to treat Ebola by using CHO cells, but we have the capacity to manufacture it in Canada as well. Our Public Health Agency of Canada developed Ebola antibodies and our National Research Council owns the CHO cell line. There are Canadian companies that could take these and manufacture a supply.
Should the government mandate that Canada have its own supply of this Ebola treatment?